This article was originally published on 12 February 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
Merck displaces GSK at the top
For the first time in recent memory, the global vaccine rankings saw a change at the top: Merck & Co displaced GSK Biologicals as the world's largest vaccine company by revenue following the 2007 reporting season. The driver was unambiguous - the extraordinary commercial performance of two products launched within the previous two years: Gardasil (HPV-4) and RotaTeq (rotavirus pentavalent). Together, these two vaccines generated revenues that no other vaccine company's launches had matched in such a short timeframe.
Gardasil's estimated global sales in 2007 - less than two years post-launch - making it the fastest vaccine to reach blockbuster status in the industry's history
What this means for the competitive order
GSK Biologicals remained a formidable competitor, with its own HPV vaccine Cervarix advancing through EU approval, and Synflorix (PHiD-CV) filed for EU registration in early 2008. Sanofi-Pasteur retained its strong position in influenza and travel vaccines, while Wyeth's Prevnar continued to generate substantial revenues despite the impending competitive challenge. The ranking change did not signal a structural weakening of GSK's position - rather, it reflected the step-change commercial impact of two exceptional new product launches by Merck.
"Gardasil alone generated revenues sufficient to transform Merck's industry ranking - a reminder that a single breakthrough product can reshape the competitive order in vaccines more rapidly than in almost any other pharmaceutical category."